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 Introduction 
 Diffuse large B-cell lymphoma (DLBCL) is the aggressive 
subgroup of non-Hodgkin’s lymphoma (NHL) and comprises 
approximately 30–40% of all cases. It is clinically and biologically 
heterogeneous disease, characterized with highly variable 
response to the treatment and clinical outcome. 1 Th e International 
Prognostic Index (IPI) deﬁ nes risk groups based on the clinical 
parameters at presentation. 2 However, patients with identical 
IPI still exhibit marked variability in survival, suggesting the 
presence of signiﬁ cant biological heterogeneity within the same 
IPI category. 3 In the recent years, much eﬀ ort has been made 
to establish new, molecular prognostic parameters in order to 
further stratify patients into diﬀ erent risk groups and choose 
appropriate treatment strategy. 4–6 Th e addition of rituximab to the 
standard CHOP chemotherapy (R-CHOP) has led to a marked 
improvement in clinical outcome of patients with DLBCL, but 
in the same time, it’s introduction has altered the signiﬁ cance of 
previously recognized prognostic parameters. 7 So, it is important 
to investigate additional molecular markers and reexamine the 
formerly established in aim to improve prognosis in the era of 
rituximab. 
 Aberrant DNA methylation of CpG islands in the promoter 
region of tumor suppressor genes represents an important 
mechanism of their inactivation. Th ere are increasing evidences 
that hypermethylation of certain genes in cancer could serve as 
marker for monitoring the clinical behavior of the disease and 
prediction of patients outcome. 8 Recent investigations showed 
that multiple genes could be aﬀ ected through aberrant DNA 
methylation in DLBCL, leading to deregulation of multiple 
cell pathways, including cell cycle control, 9,10 DNA damage 
repair, apoptosis, 11 and many others. Th ough there are strong 
evidences that such epigenetic changes could contribute to 
lymphomagenesis and the biological behavior of the disease, 12–14 
the impact of particular genes methylation on patients’ prognosis 
and outcome, especially in the era of new treatment strategies, 
remains unsolved. Hence, the aim of our study was to investigate 
the methylation status of four selected, cancer-related genes in the 
group of 51 DLBCL patients, in order to determine the possible 
association of their methylation with clinicopathogical features 
and outcome. Th e selected genes included:  p15 and  p16 tumor 
suppressor genes, encoding for cyclin-dependent kinase inhibitors 
important for G1 cell cycle arrest, 10 gene for O 6 -methylguanine-
DNA methyltransferase ( MGMT ), a DNA repair enzyme that 
removes mutagenic and cytotoxic adducts from the O 6 position 
of guanine, 15 and  DAPK (death-associated protein kinase) gene 
that encodes a serine-threonine kinase involved in the extrinsic 
pathway of apoptosis, initiated by  γ -interferon, FAS ligand, and 
tumor necrosis factor- α . 16 The promoter hypermethylation 
of these four genes has frequently been observed in DLBCL, 
indicating the important role of such epigenetic changes in the 
pathogenesis of this tumor type. 10–14 However, the data considering 
the relationship between methylation status of selected genes 
and patients’ prognosis are contradictory, which needs more 
comprehensive investigations. 
 Methods 
 Patients and samples 
 Fift y-one patients (26 male, 25 female; median age 52.4 years, 
range 19–83 years) with DLBCL included in this study were 
diagnosed and treated in the Institute of Hematology, Clinical 
Center of Serbia, Belgrade, Clinic of Hematology MMA, Belgrade, 
Serbia and Oncology Institute of Vojvodina, Sremska Kamenica, 
Serbia, from 2001 to 2012. Biopsy samples of lymph node, bone 
marrow, or other involved organs from patients were collected 
at diagnosis. Th e data according to the all clinicopathological 
parameters, overall survival (OS), as well as the presence of 
Bcl2, Bcl6, CD10, and Ki67 expression were taken from medical 
documentation of listed institutions. Tumor samples were 
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 Abstract 
 In this study, methylation-specifi c polymerase chain reaction was used to investigate the potential prognostic signifi cance of the methyla-
tion status of  p15 ,  p16, MGMT , and  DAPK genes in 51 specimens of diffuse large B-cell lymphoma (DLBCL). Hypermethylation of  p15 
gene was signifi cantly more prevalent in patients without relapse ( p = 0.001) and there was a trend toward more frequent presence 
of  p15 methylation in patients without death outcome within 5-year follow-up period ( p = 0.086) Also, there was a trend toward ac-
cumulation of  p15 methylation with favorable clinicopathological parameters including: age ≤ 60 years ( p = 0.091), normal levels of 
lactate dehydrogenase ( p = 0.090), Eastern Cooperative Oncology Group performance status < 2 ( p = 0.095), and low/intermediate 
low International Prognostic Index ( p = 0.076). In the female group and group of the patients without bulky tumor mass, treated with 
chemotherapeutic regimens including rituximab, methylation of  p15 was signifi cantly related to longer overall survival ( p = 0.036 and 
0.027, respectively). Our results suggest that promoter methylation of  p15 gene could have prognostic value in DLBCL patients treated 
with rituximab when used in combination with gender and tumor size. Clin Trans Sci 2014; Volume 7: 384–390 
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considered positive for Bcl-2, Bcl-6, or CD10 when at least 50%, 
10%, or 20% of tumor cells expressed Bcl2, Bcl6, or CD10 protein, 
respectively. Expression of Ki67 protein in 0–30% of tumor cells 
was considered as weak, in 30–60% of tumor cells as moderate, 
and in more than 60% of the cells as strong. All procedures were 
carried out with the prior informed consent of the patients 
and with the approval of the local Ethic Committee. Treatment 
consisted of CHOP/R-CHOP (cyclophosphamide, doxorubicin, 
vincristine, and prednisone with or without rituximab) regimen. 
Some patients had adjuvant radiotherapy and/or surgery, and 
some of them underwent autologous stem-cell transplantation. 
Response criteria and survival outcomes were deﬁ ned according 
to the recommendation of Cheson et al. 17 
 Analysis of methylation status of the  p15 ,  p16 ,  MGMT , and 
 DAPK genes 
 DNA methylation patterns in the promoter CpG islands of the 
 p15 ,  p16 ,  MGMT , and  DAPK genes were determined in all of 
51 samples by methylation-speciﬁ c polymerase chain reaction 
(MSP) following the bisulﬁ te modiﬁ cation of isolated genomic 
DNA, as described earlier. 18 Brieﬂ y, DNA was isolated from 
deparaﬃ  ned tumor specimens using standard proteinase K, 
phenol/chloroform/isoamyl alcohol extraction, and ethanol 
precipitation. 19 Two micrograms of isolated DNA were denatured 
by NaOH (ﬁ nal 0.3 mol/L) at 42°C for 30 minutes and modiﬁ ed 
by sodium bisulﬁ te (5.20–5.69 mol/L, pH 5.0, Sigma, St Louis, MO, 
USA) for 18 hours at 50°C . Aft er incubation, DNA was puriﬁ ed 
using the DNA extraction KIT (MBI Fermentas, Lithuania), 
again treated by NaOH (ﬁ nal 0.3 mol/L), at 37°C for 20 minutes, 
precipitated with ethanol/ammonium acetate and resuspended in 
40  μ L of 1 mmol/L Tris-HCl, pH 8.0. Aliquots of 4  μ L of bisulﬁ te-
modiﬁ ed DNA were used for MSP reactions. Th e polymerase 
chain reaction (PCR) mixture contained 1 × PCR buffer 
(16 mmol/L ammonium sulfate, 67 mmol/L Tris-HCL, pH 8.8, 
10 mmol/L 2-mercaptoethanol), 6.7 mmol/L MgCl 2 , dNTP (each at 
1.25 mmol/L), and primers (300 ng each per reaction) in a 
ﬁ nal volume of 50  μ L. Reactions were hot-started at 95°C for 
5 minutes before the addition of 1.25 units of Taq polymerase 
(MBI Fermentas). Ampliﬁ cation was carried out in an Applied 
Biosystems (Foster City, CA, USA) 2720 temperature cycler 
for 40 cycles (45 seconds at 95°C, 45 seconds at the annealing 
temperature being speciﬁ c for each reaction, and 60 seconds at 
72°, followed by ﬁ nal extension for 4 minutes at 72°C). Primers 
sequences used for each reaction are listed in  Table  1 . DNA from 
peripheral blood lymphocytes from a healthy donor was used 
as negative control for methylated alleles. Th e same leukocyte 
DNA was methylated  in vitro with excess SssI methyltransferase 
(New England Biolabs, Ipswich, MA, USA) to generate completely 
methylated DNA at all CpG sites and used as positive control for 
all genes. PCR products were separated by electrophoresis on 
6% acrylamide gels, stained with silver nitrate and visualized by 
sodium carbonate. 
 Statistical analysis 
 Contingency tables were analyzed using Pearson’ s  χ 2 -test or 
Fisher’ s exact two-tailed test, when expected frequencies were 
lower than ﬁ ve. Continuous variables were compared with the use 
of Student’ s  t -test. OS distributions were estimated by the Kaplan-
Meier method and diﬀ erences were evaluated by the Log-rank test. 
In all tests, a  p -value less than 0.05 were considered as statistically 
signiﬁ cant. All statistical analyses were performed using the Sigma 
Plot 10.0 licensed statistical analysis soft ware package. 
 Results 
 Correlation between promoter methylation status and 
clinicopathological features 
 Hypermethylation of  p15 ,  p16 ,  MGMT , and  DAPK genes was 
detected in 23% (12/51), 37%, (19/51), 39% (20/51), and 55% 
(28/51) of samples, respectively. Representative examples of the 
methylation analysis are shown in  Figure  1 . Overall, 74% (38/51) of 
cases showed at least one hypermethylated gene, and 25% (13/51) 
of cases show no methylation of any genes examined. We observed 
the signiﬁ cant correlations between methylation of  p15 and  p16 
genes ( p = 0.037),  p16 and  DAPK genes ( p = 0.047), and  MGMT 
and  DAPK genes ( p = 0.025), and observed comethylations were 
present in 16%, 27%, and 29% of cases, respectively. 
 Study of correlations between promoter methylation status 
of each gene and clinicopathological features are summarized in 
 Table  2 . Methylation of  p16 gene was signiﬁ cantly more prevalent 
in patients with normal level of lactate dehydrogenase (LDH) 
( p = 0.035) and low/intermediate low IPI score ( p = 0.034). We 
observed a trend toward more prevalent methylation of  p15 gene 
in patients younger than 60 years ( p = 0.091), normal level of 
LDH ( p = 0.090), Eastern Cooperative Oncology Group (ECOG) 
performance status <2 ( p = 0.095), and with low/intermediate low 
IPI score ( p = 0.076). In the same time, we observed signiﬁ cant 
correlation between  p15 methylation status and relapse of 
Primer set Sense primer Antisense primer Size (bp)/AT References 
p15-M 5’-GCGTTCGTATTTTGCGGTT-3’ 5’-CGTACAATAACCGAACGACCGA-3’ 148 bp/57°C  20 
p15-U 5’-TGTGATGTGTTTGTATTTTGTGGTT-3’ 5’-CCATACAATAACCAAACAACCAA-3’ 154 bp/57°C  20 
p16-M 5’-TTATTAGAGGGTGGGGCGGATCGC-3’ 5’-GACCCCGAACCGCGACCGTAA-3’ 150 bp/65°C  20 
p16-U 5’-TTATTAGAGGGTGGGGTGGATTGT-3’ 5’-CAACCCCAAACCACAACCATAA-3’ 151 bp/60°C  20 
MGMT-M 5’-TTTCGACGTTCGTAGGTTTTCGC-3’ 5’-GCACTCTTCCGAAAACGAAACG-3’ 81 bp/57°C  21 
MGMT-U 5’-TTTGTGTTTGATGTTTGTAGGTTTTTGT-3’ 5’-AACTCCACACTCTTCCAAAAACAAAAA-3’ 93 bp/57°C  21 
DAPK-M 5’-GGATAGTCGGATCGAGTTAACGTC-3’ 5’-CCCTCCCAAACGCCGA-3’ 98 bp/60°C  22 
DAPK-U 5’-GGAGGATAGTTGGATTGAGTTAATGTT-3’ 5’-CAAATCCCTCCCAAACACCAA-3’ 106 bp/60°C  22 
 M = primer set for methylated modifi ed DNA sequence; U = primer set for unmethylated modifi ed DNA sequence; AT = annealing temperature. 
 Table 1.  Primer sets used for MSP. 
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the disease; no one patient with relapsed DLBCL showed  p15 
methylation ( p = 0.001,  Table  2 ). Also, there was a trend toward 
more frequent presence of  p15 methylation in patients without 
death outcome within 5-year follow-up period ( p = 0.086). Th ere 
was no correlation between methylation of  MGMT or  DAP K genes 
with any clinicopathological characteristic, Bcl2, Bcl6, CD10, and 
Ki67 expression, response to the therapy or patients’ outcome. 
 Clinicopathological features of the group with concomitant 
 p15 and  p16 methylation ( p15m/p16m ) 
 We found that methylation of  p15 gene occurs signiﬁ cantly 
more frequent with simultaneous methylation of  p16 gene 
than as a single event (67% vs. 33%,  p = 0.037). We have also 
observed a tendency toward accumulation of  p15m/p16m with 
clinicopathological characteristics related to less aggressiveness 
of the disease, including: female gender ( p = 0.140), normal 
LDH levels ( p = 0.100), age less than 60 years ( p = 0.119), ECOG 
performance status < 2 ( p = 0.127), low/intermediate low IPI 
score ( p = 0.099). In addition, none of the patients with  p15m/
p16m had relapsed disease during follow-up period ( p = 0.031). 
 Survival analysis in the whole group of DLBCL patients 
 Follow-up data were available for 46/51 patients and the median 
follow-up period was 30.5 months (range 1–111 months). Five-
year survival for the entire group was 61% (95% CI: 45.25–74.42). 
OS was signiﬁ cantly worse for patients who were in any of the 
following categories: intermediate high/high IPI risk group ( p = 
0.033), ECOG performance status ≥ 2 ( p < 0.001) B symptoms 
present ( p = 0.027), no Bcl6 expression ( p = 
0.050), no response to the initial therapy ( p 
< 0.001), and not treated with rituximab ( p 
= 0.031). Among all patients with DLBCL, 
there was no signiﬁ cant diﬀ erence in the OS 
between those with hypermethylated and 
unmethylated of any examined genes ( p > 0.05 
in all cases,  Figure  2 ). However, patients with 
methylated  p15 tended to have longer OS in 
contrast to those with unmethylated  p15 gene, 
though this diﬀ erence was not statistically 
signiﬁ cant ( p = 0.155,  Figure   2 A). Th ere was no 
signiﬁ cant diﬀ erence in OS between patients 
with hypermethylated and unmethylated of 
any examined genes in the diﬀ erent groups 
according to the IPI or any other group of the 
patients classiﬁ ed according to the parameters 
given in the  Table  2 . 
 Survival analysis in the group of the 
patients treated with multidrug regimens 
including rituximab 
 Considering our finding that DLBCL 
patients treated with rituximab in 
addition to the standard chemotherapy 
had significantly longer OS ( p = 0.031, 
 Figure  3 A), we further evaluated the 
impact of the methylation status of four 
examined genes on survival in this group 
of the patients. Five-year survival for the 38 
patients who received rituximab was 65% 
(95% CI: 47.93–79.32). OS was signiﬁ cantly 
worse for patients with ECOG performance status ≥ 2 ( p < 0.001), 
no Bcl6 expression ( p = 0.043), no response to the initial therapy 
( p < 0.001), and with relapsed disease ( p = 0.009). As in the whole 
group of the patients, we observed a trend toward longer OS for 
the patients with methylated  p15 gene ( p = 0.093,  Figure  3 B). 
We found no signiﬁ cant diﬀ erence in OS between patients with 
hypermethylated and unmethylated  p15 gene according to the IPI 
(results not shown). However,  p15 methylation was signiﬁ cantly 
related to longer OS in the female group of the patients ( p = 
0.036,  Figure  3 C) and in those with no bulky tumor mass ( p = 
0.027,  Figure  3 D). Moreover, in both cases, all patients with  p15 
methylation were alive during follow-up period. No signiﬁ cant 
impact on OS was seen for the other three genes in the any group 
of the patients treated with R-CHOP (results not shown). 
 Discussion 
 Prognostic utility of epigenetic changes in malignant lymphoma, 
especially in the era of new therapy regimens, is still not clearly 
determined. In the present study, we investigated the biological 
signiﬁ cance and the prognostic relevance of the methylation status 
of four cancer-related genes in a series of 51 DLBCL, most of them 
treated with rituximab in addition to standard chemotherapy. 
Aberrant methylation of  p15 ,  p16, MGMT , and  DAPK genes was 
detected in 23%, 37%, 39%, and 55% of patients, respectively. 
Thirty-eight of 51 patients (75%) had methylation of more 
than one examined genes. Our ﬁ ndings indicate that epigenetic 
alterations are common phenomenon in DLBCL and may be 
important for pathogenesis of this group of NHL. 
 Figure 1.  Analysis of  p15 ,  p16 ,  MGMT , and  DAPK genes methylation by MSP in representative cases of DLBCL. 
The presence of a visible PCR product in lanes U indicates the presence of unmethylated allels (154, 151, 93, and 
106 bp, respectively), while the presence of product in lanes M indicates the presence of methylated allels (148, 
150, 81, and 98 bp, respectively). NL = normal lymphocytes as a positive control for unmethylated allels; PC = 
 in vitro methylated DNA from normal lymphocytes as a positive control for methylated allels; MW = molecular 
weight marker (50 bp). 
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Variable p15m p16m MGMTm DAPKm  p 
Gender 
 Male 4/26 (15%) 9/26 (35%) 11/26 (42%) 14/26 (54%)  
 Female 8/25 (32%) 10/25 (40%) 9/25 (36%) 14/25 (56%) NS 
Age (yr) 
 ≤60 10/30 (33%) 14/30 (47%) 14/30 (47%) 19/30 (63%)  
 >60 2/21 (9%)* 5/21 (24%) 6/21 (29%) 9/21 (43%) 0.091* 
Stage 
 I, II 2/8 (25%) 4/8 (50%) 2/8 (25%) 5/8 (62%)  
 III, IV 10/43 (23%) 15/43 (35%) 18/43 (42%) 23/43 (53%) NS 
LDH 
 Normal 7/20 (35%)** 11/20 (55%)* 7/20 (35%) 12/20 (60%) 0.035* 
 Elevated (>450 u/L) 4/29 (14%) 6/29 (21%) 12/29 (41%) 14/29 (48%) 0.090** 
Extranodal sites 
 0, 1 10/39 (26%) 14/39 (36%) 14/39 (36%) 20/39 (51%)  
 >1 2/12 (17%) 5/12 (42%) 6/12 (50%) 8/12 (67%) NS 
ECOG performance status 
 <2 10/35 (29%)* 14/35 (40%) 13/35 (37%) 21/35 (60%)  
 ≥2 2/16 (12%) 5/16 (31%) 7/16 (44%) 7/16 (45%) 0.095* 
IPI score 
 Low/intermediate low 7/17 (41%)** 10/17(59%)* 7/17 (41%) 12/17 (71%) 0.034* 
 Intermediate high/high 5/34 (15%) 9/34 (26%) 13/34 (38%) 16/34 (47%) 0.076** 
B symptoms 
 Absent 4/16 (25%) 7/16 (44%) 4/16 (25%) 8/16 (50%)  
 Present 7/33 (21%) 12/33 (36%) 15/33 (45%) 18/33 (54%) NS 
BM involvement 
 Absent 9/32 (28%) 13/32 (41%) 13/32 (41%) 20/32 (62%)  
 Present 3/19 (16%) 6/19 (32%) 7/19 (37%) 8/19 (42%) NS 
Bulky tumor (≥10 cm) 
 Absent 9/38 (24%) 15/38 (39%) 15/38 (39%) 21/38 (55%)  
 Present 3/11 (27%) 4/11 (36%) 4/11 (36%) 5/11 (45%) NS 
Bcl-2 expression 
 Absent 6/28 (21%) 11/28 (39%) 9/28 (32%) 14/28 (50%)  
 Present 4/18 (22%) 4/18 (22%) 8/18 (44%) 9/18 (50%) NS 
Bcl-6 expression 
 Absent 1/12 (8%) 5/12 (42%) 5/12 (42%) 7/12 (58%)  
 Present 5/23 (22%) 8/23 (35%) 6/23 (26%) 11/23 (48%) NS 
CD10 expression 
 Absent 1/12 (8%) 4/12 (33%) 5/12 (42%) 6/12 (50%)  
 Present 3/11 (27%) 3/11 (27%) 5/11 (45%) 7/11 (64%) NS 
Ki67 expression 
 Weak/moderate 3/15 (20%) 5/15 (33%) 5/15 (33%) 7/15 (47%)  
 High 6/21 (29%) 7/21 (33%) 8/21 (38%) 12/21 (57%) NS 
Response to treatment 
 CR/PR 10/41 (24%) 14/41 (34%) 16/41 (39%) 21/41 (51%)  
 Table 2.  Continued. 
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 Tumor suppressor genes  p15 and  p16 are the members of 
cyclin-dependent kinase inhibitors and are frequently inactivated 
by aberrant hypermethylation of promoter CpG islands in 
various hematological tumors. 23,24 In DLBCL, methylation of 
 p15 and  p16 genes has been found in 32–77% and 27–54% of 
cases, respectively 10,13,14,24–26 and the results obtained in our study 
are similar to those in previous reports. However, prognostic 
signiﬁ cance of  p15 and  p16 methylation in DLBCL is unclear. While 
some studies have found  p16 methylation 
as a marker of worse prognosis 13,14,27 some 
others have not. 26,28 In our study, methylation 
of  p16 gene was not related with patients 
outcome. However, we demonstrated 
a significant correlation between  p16 
hypermethylation and normal level of LDH 
and low/intermediate low IPI score. Th ese 
two parameters have been related to better 
prognosis in many studies, 2,13,14,29 which is 
conﬁ rmed for IPI in ours. To our knowledge, 
we are the ﬁ rst to detect such associations, 
so the importance of our results should be 
conﬁ rmed in the further studies on the larger 
number of samples. 
 While there are reports about impact 
of  p15 promoter methylation on patient’s 
prognosis in various cancer types, 30–32 such 
influence in DLBCL, to our knowledge, 
was not found till now. 13,14,26 In the present 
study, we observed a signiﬁ cant correlation 
between  p15 hypermethylation and longer 
OS in the female patients and those with no 
bulky tumor mass, treated with rituximab 
in addition to standard chemotherapy. 
In the same time, we observed a trend 
toward longer OS in the whole group of the 
patients under given treatment. Th e precise 
mechanism underlying such favorable impact 
is unknown. Of notice, the prevalence of  p15 
methylation was twice as higher in female 
than in male patients from our study, though 
this diﬀ erence was not statistically signiﬁ cant 
(32% vs. 15%,  Table  2 ). There are some 
reports about gender-associated diﬀ erences 
in DNA methylation at speciﬁ c loci, but the 
results are controversial. 33 In addition, male 
gender was recently reported as an adverse prognostic factor in 
DLBCL patients treated with R-CHOP. Th e possible explanation 
for observed diﬀ erences among genders in our study could be 
the diﬀ erence in blood clearance of rituximab between males and 
females, which cause the better response of women to rituximab. 34 
Th ough not signiﬁ cant, a tendency toward accumulation of  p15 
and simultaneous  p15/p16 methylation with clinicopathological 
characteristics related to better prognosis is observed in the whole 
Variable p15m p16m MGMTm DAPKm  p 
 NR 1/8 (12%) 4/8 (50%) 3/8 (37%) 6/8 (75%) NS 
Relapse 
 Absent 11/31 (35%)* 13/31 (42%) 10/31 (32%) 17/31 (55%)  
 Present 0/18 (0%) 5/18 (28%) 8/18 (44%) 8/18 (44%) 0.001* 
Death outcome within 5 years 
 Absent 9/27 (33%)* 11/27 (41%) 10/27 (37%) 16/27 (59%)  
 Present 2/20 (10%) 6/20 (30%) 8/20 (40%) 9/20 (45%) 0.086* 
 LDH = lactate dehydrogenase; ECOG = Eastern Cooperative Oncology Group; BM = bone marrow; CR = complete remission; PR = partial remission; NR = no response; 
NS = not signifi cant. * and ** relates signifi cant p values with appropriate gene and examined clinicopathological characteristics. For the cases where methylation status of two 
genes is related to appropriate clinicopathological characteristic (LDH and IPI score), * relates appropriate p value with p16 gene, and ** with p15 gene. 
 Table 2.  Correlation of  p15 ,  p16 ,  MGMT , and  DAPK methylation status with clinicopathological features in DLBCL. 
 Figure 2.  Overall survival (OS) in the entire group of DLBCL patients according to the methylation status of 
(A)  p15 , (B)  p16 , (C)  MGMT , and (D)  DAPK gene. No signifi cant differences were observed in OS between 
patients with methylated and unmethylated any of examined genes. The greatest difference in OS is observed 
in the case of  p15 gene, where patients with methylated  p15 tended to have longer OS than the patients with 
unmethylated  p15 gene. 
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group of the patients. So, we suggest that  p16 and especially  p15 
methylation could be related to better prognosis in DLBCL, though 
the precise mechanism is unknown. Considering that methylation 
of both,  p15 and  p16 , genes is more prevalent in lower IPI patients 
from our study, it is possible that their inactivation in higher IPI 
DLBCLs is achieved by some other mechanisms, including deletions. 
As described earlier, homozygous deletions of  p15 and  p16 are 
present in approximately one-third of the DLBCL, predominantly 
in activated B-cell subtype of DLBCL (ABC), where they are 
related to a poor prognosis. 27,35–37 On the contrary, methylation of 
these two genes is predominant mechanism of their inactivation 
in germinal center B-cell subtype of DLBCL (GCB), 37 which has 
better prognosis and distinct epigenetic and genetic signature 
than ABC-DLBCL. 4,5 Moreover, Guney et al. 37 have found that 
inactivation of  p15 and  p16 genes in GBC subtype is monoallelic, 
while in ABC subtype is biallelic. In addition, they demonstrated 
higher methylation levels of  p15 and  p16 promoters in the DLBCL 
cases with simultaneous heterozygous deletions of the second allel, 
compared to the methylation level of undeleted cases. Considering 
these results, we suppose that the expression of  p15 and/or  p16 in 
such types of DLBCL is not completely suppressed. It could be 
supported by ﬁ nding of Cameron et al., 38 who showed that the 
extent of methylation is a critical determinant of the degree to 
which  p15 is silenced in primary acute leukemia. It is possible that 
DLBCL patients with  p15 and/or  p16 methylation from our study 
belong to the GCB subtype, so it could be, 
at least, partially explanation for our results. 
Also, it is possible that in more aggressive 
DLBCL some other genetic and/or epigenetic 
alterations exist that are related to more 
aggressive behavior of the disease. Previous 
studies have shown that  p16 methylation is 
related to more aggressive phenotype only 
when simultaneous inactivation of  p53 ,  p14 , 
and  p27 genes is present. 25,39 However, as we 
did not have enough data to distinguish our 
DLBCL samples on GBC and ABC subtypes, 
further investigations are needed to conﬁ rm 
our hypothesis and completely elucidate the 
role of  p15 and  p16 hypermethylation in 
DLBCL. 
 MGMT is a well-known DNA repair 
gene, important for protecting cells from 
mutagenic and cytotoxic adducts originated 
from the environmental and therapeutic 
alkylating agents. 15 Inactivation of  MGMT 
due to promoter hypermethylation occurs 
at varying frequencies throughout the entire 
spectrum of B-cell neoplasms. 11,40 We detected 
 MGMT methylation in 39% of our cases, 
which is in line with observed frequencies 
in other studies on DLBCL. 11,21,41 Previous 
studies on DLBCL demonstrated that  MGMT 
methylation could be a useful marker for 
predicting survival in patients treated with 
multidrug regimens, including the alkylation 
agent cyclophosphamide. 12 However, these 
results were obtained before the introduction 
of rituximab to the chemotherapy. Recent 
studies on DLBCL patients who received 
R-CHOP showed that inactivation of  MGMT 
gene does not play a role as a predictive marker of response to this 
treatment and in predicting survival. It is postulated that rituximab 
may play an important role in overcoming chemoresistance to 
cyclophosphamide, especially in the  MGMT unmethylated group. 42 
Our results are in concordance with this ﬁ nding, as we observed 
no diﬀ erence in the response to the therapy or OS according to the 
methylation status of  MGMT gene. 
 Inactivation of  DAPK gene by aberrant promoter 
hypermethylation is common event in B-cell malignancies, 
including DLBCL, where it is occurring in approximately 60% 
of cases. 11,14,22,41,43 Our results are similar with those in previous 
reports.  DAPK is a pro-apoptotic serine/threonine kinase, 
involved in multiple apoptosis pathways, so its inactivation could 
be a key factor modulating the response to chemotherapy in 
human cancer. 16,44 While Amara et al. 14 have found that  DAPK 
hypermethylation is an independent prognostic factor in predicting 
shortened OS of DLBCL patients, Nakamichi et al. 45 have found 
no impact of  DAPK methylation on patients’ outcome. Th e latter 
ﬁ nding is in concordance with our results, so further analyses are 
necessary to elucidate the prognostic utility of  DAPK in DLBCL. 
 Conclusion 
 Although obtained results need to be conﬁ rmed in larger series, 
our study suggests that methylation of  p15 gene could have 
prognostic value in DLBCL patients treated with rituximab when 
 Figure 3.  Overall survival (OS) in the DLBCL patients treated with rituximab. (A) OS is signifi cantly longer in patients 
treated with rituximab in addition to the standard chemotherapy; (B) patients with methylated  p15 tended to have 
longer OS than patients with unmethylated  p15 gene; (C) female patients with methylated  p15 had signifi cantly 
longer OS than those with unmethylated  p15 gene; (D) patients with no bulky tumor mass with methylated  p15 
had signifi cantly longer OS than those with unmethylated  p15 gene. 
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used in combination with gender and tumor size. It is possible 
that  p15 hypermethylation is not a prognostic marker by itself, 
but identiﬁ es a speciﬁ c pathogenetic subset of lymphomas with 
a more favorable outcome. However, further investigations are 
needed to conﬁ rm our hypothesis and clarify the role of  p15 gene 
methylation in the pathogenesis of DLBCL. 
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